Article Versions Notes

Gordon EM, Chawla SP, Tellez WA, Younesi E, Thomas S, Chua-Alcala VS, Chomoyan H, Valencia C, Brigham DA, Moradkhani A, et al. SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma. Cancers. 2023; 15(3):906. https://doi.org/10.3390/cancers15030906

Gordon, Erlinda Maria, Sant P. Chawla, Walter Andree Tellez, Elan Younesi, Sonu Thomas, Victoria S. Chua-Alcala, Hripsime Chomoyan, Chrysler Valencia, Don Arlen Brigham, Ania Moradkhani, and et al. 2023. "SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma" Cancers 15, no. 3: 906. https://doi.org/10.3390/cancers15030906

Gordon, E. M., Chawla, S. P., Tellez, W. A., Younesi, E., Thomas, S., Chua-Alcala, V. S., Chomoyan, H., Valencia, C., Brigham, D. A., Moradkhani, A., Quon, D., Srikureja, A., Wong, S. G., Tseng, W., & Federman, N. (2023). SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma. Cancers, 15(3), 906. https://doi.org/10.3390/cancers15030906